Literature DB >> 10431014

Acute and chronic hepatic allograft rejection: pathology and classification.

K P Batts1.   

Abstract

Hepatic allograft rejection has been divided into humoral (or hyperacute), acute (or cellular), and chronic (or ductopenic) forms. Humoral rejection is extremely uncommon in the liver and is not graded. Acute rejection will occur in approximately 50% of liver allografts, is more common in the first few weeks posttransplantation, and is defined by Snover's triad of portal hepatitis, endothelialitis (or endotheliitis), and lymphocytic cholangitis. This form of rejection is generally reversible, either spontaneously or with additional immunosuppressive therapy, and can be reliably graded using a system with categories of mild, moderate, and severe rejection, associated with 37%, 48%, and 75% unfavorable shortterm and 1%, 12%, and 14% unfavorable long-term outcomes, respectively. Chronic rejection is characterized histologically by progressive duct loss and a lipid-rich vasculopathy that can be difficult to diagnose in early phases. Chronic rejection typically occurs several months to a year posttransplantation, although exceptions exist.

Entities:  

Mesh:

Year:  1999        PMID: 10431014     DOI: 10.1053/JTLS005s00021

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  9 in total

1.  18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.

Authors:  Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

2.  Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Authors:  John C Hoefs; Mitchell L Shiffman; Zachary D Goodman; David E Kleiner; Jules L Dienstag; Anne M Stoddard
Journal:  Gastroenterology       Date:  2011-06-12       Impact factor: 22.682

Review 3.  Aetiology and risk factors of ischaemic cholangiopathy after liver transplantation.

Authors:  Moustafa Mabrouk Mourad; Abdullah Algarni; Christos Liossis; Simon R Bramhall
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

4.  Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  James E Everhart; Elizabeth C Wright; Zachary D Goodman; Jules L Dienstag; John C Hoefs; David E Kleiner; Marc G Ghany; A Scott Mills; S Russell Nash; Sugantha Govindarajan; Thomas E Rogers; Joel K Greenson; Elizabeth M Brunt; Herbert L Bonkovsky; Chihiro Morishima; Heather J Litman
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

5.  Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance.

Authors:  Toshiaki Nakano; Chia-Yun Lai; Shigeru Goto; Li-Wen Hsu; Seiji Kawamoto; Kazuhisa Ono; Kuang-Den Chen; Chih-Che Lin; King-Wah Chiu; Chih-Chi Wang; Yu-Fan Cheng; Chao-Long Chen
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

6.  Acute Hepatic Allograft Rejection in Pediatric Recipients: Independent Factors.

Authors:  S M Dehghani; I Shahramian; M Afshari; M Bahmanyar; M Ataollahi; A Sargazi
Journal:  Int J Organ Transplant Med       Date:  2017-11-01

7.  Acute Hepatic Allograft Rejection in Pediatric Recipients: Effective Factors.

Authors:  S M Dehghani; I Shahramian; M Afshari; M Bahmanyar; M Ataollahi; A Sargazi
Journal:  Int J Organ Transplant Med       Date:  2018-02-01

8.  Low Serum Levels of (Dihydro-)Ceramides Reflect Liver Graft Dysfunction in a Real-World Cohort of Patients Post Liver Transplantation.

Authors:  Victoria Therese Mücke; Janis Gerharz; Katja Jakobi; Dominique Thomas; Nerea Ferreirós Bouzas; Marcus Maximilian Mücke; Sven Trötschler; Nina Weiler; Martin-Walter Welker; Stefan Zeuzem; Josef Pfeilschifter; Georgios Grammatikos
Journal:  Int J Mol Sci       Date:  2018-03-26       Impact factor: 5.923

9.  Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.

Authors:  Masaki Takinami; Akira Ono; Takanori Kawabata; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Masahiro Endo; Yoshio Kiyohara; Hirofumi Yasui; Masashi Niwakawa; Toshiaki Takahashi
Journal:  Invest New Drugs       Date:  2021-05-28       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.